Company profile
Clene Inc.
NASDAQ:CLNNBiotechnology: Pharmaceutical Preparations
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03843710 | phase2 | withdrawn | 2020-03-01 | 2022-02-01 | Clene Nanomedicine | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) |
| NCT03993171 | phase2 | completed | 2019-12-19 | 2025-05-27 | Clene Nanomedicine | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. |
| NCT03815916 | phase2 | completed | 2019-12-19 | 2021-06-07 | Clene Nanomedicine | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease |
| NCT04626921 | phase2_3 | completed | 2020-10-22 | 2023-05-29 | Clene Nanomedicine | A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis |
| NCT05299658 | phase2 | active_not_recruiting | 2021-11-13 | 2026-06-01 | Clene Nanomedicine | An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS |
FDA applications (0)
No records yet.